Mirum Pharmaceuticals Inc (MIRM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.14B
Last updated: Nov 17, 2026 at 11:05 AM ET
Mirum Pharmaceuticals Inc (MIRM) Financials: Revenue, Profit and Cash Flow
Mirum Pharmaceuticals reported revenue of $521.31M for the fiscal year ended Dec 31, 2025, up 54.7% from the year before. That year, net income was -$23.36M with a net margin of -4.5%, operating cash flow was $55.83M and free cash flow was $54.87M. The quarter ended Sep 30, 2026 had revenue of $185.72M and net income of -$40.77M.
Revenue and Margins
The operating margin was -4.2% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $521.31M | +54.7% | 80.8% | -4.2% | -4.5% |
| Dec 2024 | $336.89M | +80.8% | 75.8% | -26.0% | -26.1% |
| Dec 2023 | $186.37M | +141.8% | 74.8% | -58.6% | -87.7% |
| Dec 2022 | $77.06M | +302.7% | 83.9% | -170.3% | -176.0% |
| Dec 2021 | $19.14M | N/A | 100.0% | -906.1% | -438.9% |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $521.31M | $336.89M | $186.37M | $77.06M | $19.14M | $0 | $0 | $0 |
| Cost of revenue | $100.24M | $81.64M | $47.04M | $12.37M | $0 | $0 | $0 | $0 |
| Gross profit | $421.07M | $255.25M | $139.34M | $64.69M | $19.14M | $0 | $0 | $0 |
| Research and development | $186.18M | $140.63M | $102.61M | $106.84M | $131.43M | $81.61M | $42.99M | $2.33M |
| Operating income | -$22.14M | -$87.61M | -$109.15M | -$131.22M | -$173.41M | -$104.30M | -$54.74M | -$2.92M |
| Net income | -$23.36M | -$87.94M | -$163.41M | -$135.66M | -$83.99M | -$103.27M | -$52.55M | -$17.35M |
| EBITDA | $6.22M | -$61.10M | -$100.03M | -$127.08M | -$66.27M | -$103.94M | N/A | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $185.72M | $176.24M | $159.88M | $148.93M | $133.01M | $127.78M | $111.58M | $99.41M | $90.38M | $77.88M | $69.22M | $69.55M |
| Gross profit | $150.55M | $145.90M | $131.08M | $120.67M | $107.47M | $104.36M | $88.57M | $76.63M | $69.57M | $57.65M | $51.39M | $44.53M |
| Operating income | -$59.75M | -$42.54M | -$789.47M | -$4.57M | $2.60M | -$4.99M | -$15.18M | -$24.22M | -$12.68M | -$24.23M | -$26.47M | -$32.59M |
| Net income | -$40.77M | -$67.23M | -$790.15M | -$5.73M | $2.90M | -$5.86M | -$14.68M | -$23.79M | -$14.23M | -$24.64M | -$25.28M | -$35.66M |
Balance Sheet
As of Dec 2025, total debt of $311.94M exceeded cash and equivalents by $15.25M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $842.81M | $670.75M | $646.62M | $352.91M | $294.65M | $240.86M | $146.71M | $51.98M |
| Current assets | $549.68M | $392.79M | $387.54M | $190.22M | $166.59M | $236.35M | $119.36M | $51.98M |
| Cash and equivalents | $296.68M | $222.50M | $286.33M | $28.00M | $31.34M | $142.09M | $11.97M | $51.96M |
| Total liabilities | $528.12M | $445.11M | $397.95M | $210.87M | $174.44M | $68.77M | $16.36M | $2.45M |
| Short-term debt | $2.14M | $1.71M | $1.10M | $931.00K | $711.00K | $636.00K | $397.00K | $0 |
| Long-term debt | $309.80M | $308.08M | $306.42M | $0 | N/A | N/A | N/A | $0 |
| Shareholder equity | $314.69M | $225.64M | $248.67M | $142.04M | $120.21M | $172.09M | $130.35M | -$17.31M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.03B | $1.04B | $890.92M | $842.81M | $785.12M | $725.83M | $690.25M | $670.75M | $667.89M | $660.75M | $651.96M | $646.62M |
| Total liabilities | $1.08B | $1.06B | $648.42M | $528.12M | $493.07M | $470.67M | $456.99M | $445.11M | $435.87M | $431.77M | $417.36M | $397.95M |
| Cash and equivalents | $243.19M | $330.73M | $324.91M | $296.68M | $282.02M | $228.12M | $211.82M | $222.50M | $222.97M | $233.25M | $302.84M | $286.33M |
| Shareholder equity | -$54.19M | -$10.42M | $242.49M | $314.69M | $292.05M | $255.16M | $233.26M | $225.64M | $232.02M | $228.99M | $234.60M | $248.67M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.3% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $55.83M | $10.32M | -$70.94M | -$120.14M | -$132.76M | -$89.08M | -$39.36M | -$373.00K |
| Capital expenditures | $954.00K | $993.00K | $109.00K | $278.00K | $24.00K | $225.00K | $281.00K | $7.50M |
| Free cash flow | $54.87M | $9.33M | -$71.05M | -$120.41M | -$132.78M | -$89.30M | -$39.64M | -$7.87M |
| Dividends paid | N/A | N/A | N/A | $5.55M | $0 | N/A | N/A | $0 |
| Share repurchases | $0 | $0 | $281.00K | $0 | $0 | N/A | $0 | N/A |
| Investing cash flow | -$23.95M | -$90.13M | -$107.20M | $7.70M | $48.55M | $37.87M | -$127.78M | -$7.50M |
| Financing cash flow | $40.14M | $17.70M | $336.60M | $109.09M | $73.47M | $181.29M | $127.18M | $59.84M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.31M | -$44.25M | -$228.76M | $6.07M | $39.68M | $12.04M | -$1.96M | -$5.07M | $3.98M | -$3.80M | $15.21M | -$16.62M |
| Capital expenditures | $1.30M | $23.00K | $664.00K | $600.00K | $187.00K | $126.00K | $41.00K | $20.00K | $181.00K | $779.00K | $13.00K | $5.00M |
| Free cash flow | -$5.62M | -$44.27M | -$229.43M | $5.47M | $39.49M | $11.91M | -$2.00M | -$5.09M | $3.80M | -$4.58M | $15.20M | -$21.62M |
Frequently Asked Questions About MIRM
What is Mirum Pharmaceuticals' annual revenue?
Mirum Pharmaceuticals reported revenue of $521.31M for the fiscal year ended Dec 31, 2025.
How fast is Mirum Pharmaceuticals' revenue growing?
Revenue was up 54.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 89.1%.
Is Mirum Pharmaceuticals profitable?
No. Mirum Pharmaceuticals reported net income of -$23.36M for the fiscal year ended Dec 31, 2025, with a net margin of -4.5%.
How much free cash flow does MIRM generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $55.83M minus capital expenditures of $954.00K produced free cash flow of $54.87M.
How much debt does Mirum Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $309.80M, short-term debt of $2.14M and cash and equivalents of $296.68M.
MIRM pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts